Highlights Idorsia Ltd

Equities

IDIA

CH0363463438

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
1.9 ^CHF	+9.07%		-3.55%	-10.12%

Apr. 26	Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	MT
Apr. 11	Swiss Market Index Falls as ECB Signals June Rate Cut	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	Apr. 26	MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	Mar. 18	MT
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod	Feb. 28	MT
Switzerland's Idorsia Seeks Additional Funding to Extend Cash Runway in FY24	Jan. 10	MT
Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023	Nov. 03	CI
Idorsia Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Idorsia Returns to Profitability in Q3 as Net Revenues Expand	23-10-24	MT
Idorsia Ltd Updates Earnings Guidance for the Year 2023	23-10-24	CI
Idorsia to Buy Back Hypertension Drug Rights from Janssen Biotech in Up to CHF306 Million Deal	23-09-06	MT
Idorsia Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-25	CI
Switzerland's Idorsia Posts Lower H1 Attributable Loss; Revenue Rises	23-07-25	MT
Idorsia Ltd. Re-Issues its Financial Guidance for Full Year 2023	23-07-25	CI
Sosei Acquires Idorsia Pharmaceuticals Japan and Korea for 65 Billion Yen; Shares up 11%	23-07-20	MT
Japan's Sosei buys Idorsia Pharma's Japan, Korea units for $466 million	23-07-20	RE
Swiss Biotech Idorsia Sells Japan, South Korea Affiliates to Sosei	23-07-20	MT
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 mln	23-07-20	RE
Sosei Group Corporation completed the acquisition of Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd.	23-07-19	CI
Idorsia Launches Chronic Insomnia Drug Quviviq in Switzerland	23-06-12	MT
Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning	23-06-12	CI
Idorsia Negotiates CHF400 Million Deal for Asia Pacific Operations	23-06-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Idorsia Ltd

Equities

IDIA

CH0363463438

Highlights

Filters